stockrowHumacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022.
- Revenue
- +34.9%
- EPS
- +33.3%
- Free cash flow
- +17.9%
- Total debt
- +437.5%
Quarter to June 2026, against a year earlier
Follow HUMA
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Cash and Short Term Investments |
50.50 | 44.94 | 80.45 | 151.88 | 225.50 | 39.93 |
Receivables |
0.44 | — | — | 0.03 | 0.18 | 0.11 |
Inventory |
13.59 | — | — | — | — | — |
Total current assets |
67.80 | 47.86 | 83.28 | 154.21 | 229.34 | 41.45 |
Property, Plant, Equpment (Net) |
18.54 | 23.06 | 26.79 | 30.04 | 35.03 | 40.98 |
Long-term assets (Other) |
30.03 | 66.95 | 18.15 | 20.06 | 21.43 | 23.49 |
Total non-current assets |
48.57 | 90.01 | 44.95 | 50.09 | 57.19 | 65.24 |
Total Assets |
116.37 | 137.87 | 128.22 | 204.30 | 286.53 | 106.69 |
Notes Payable |
— | — | — | 8.57 | — | 2.45 |
Accounts Payable |
5.40 | 4.49 | 6.49 | 1.60 | 2.09 | 2.27 |
Accrued Expenses |
10.54 | 11.42 | 9.34 | 7.11 | 6.76 | 4.59 |
Current Part of Capital Lease |
2.43 | 2.92 | 2.56 | 2.26 | 1.98 | 1.73 |
Current Tax Liabilities (Deferred) |
— | — | — | — | 0.17 | 0.15 |
Other current liabilities |
— | 1.12 | — | 7.11 | 6.76 | 4.59 |
Total current liabilities |
18.37 | 19.95 | 18.44 | 19.58 | 11.05 | 11.23 |
Long Term Debt (Total) |
62.42 | 13.62 | 16.29 | 39.19 | 48.47 | 23.09 |
Long Term Tax Liability (Deferred) |
— | — | — | — | — | 0.14 |
Preferred Shares of Subsidiary (Mandatory, Redeemable) |
— | — | — | — | — | 420.99 |
Non-current Liabilities (Other) |
32.47 | 156.97 | 79.94 | 28.61 | 104.16 | 0.82 |
Total non-current liabilities |
94.89 | 170.59 | 96.23 | 67.79 | 153.31 | 445.77 |
Total liabilities |
113.26 | 190.54 | 114.68 | 87.37 | 164.36 | 457.01 |
Additional Paid In Capital |
729.94 | 633.33 | 550.85 | 543.46 | 536.74 | 37.78 |
Common Stock (Net) |
0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Retained Earnings |
(726.85) | (686.01) | (537.31) | (426.54) | (414.57) | (388.10) |
Common Equity (Total) |
3.11 | (52.67) | 13.55 | 116.93 | 122.17 | (350.32) |
Shareholders Equity (Total) |
3.11 | (52.67) | 13.55 | 116.93 | 122.17 | (350.32) |
Shareholders Equity and Liabilities (Total) |
116.37 | 137.87 | 128.22 | 204.30 | 286.53 | 106.69 |
Shares (Common) |
193.00 | 130.03 | 103.67 | 103.23 | 103.00 | 5.82 |
Shareholders Equity (Tangible) |
3.11 | (52.67) | 13.55 | 116.93 | 122.17 | (350.32) |
Net Debt |
11.92 | (31.32) | (64.15) | (112.69) | (177.03) | (16.84) |
Total Debt |
62.42 | 13.62 | 16.29 | 39.19 | 48.47 | 23.09 |